AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38714459 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA assessment of total occlusions (TOs)
Number of subjects: 114
Study 38714557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of age at diabetes diagnosis
Number of subjects: 15773
Study 38714557 — intervention group
Group type: COMPARATOR
Intervention: Higher quartiles of age at diabetes diagnosis
Number of subjects: 15773
Study 38714632 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatrifast vitamin/mineral formula
Number of subjects: 20
Study 38714692 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day artemether-lumefantrine regimen
Number of subjects: 303
Study 38714692 — intervention group
Group type: COMPARATOR
Intervention: 3-day artemether-lumefantrine regimen
Number of subjects: 303
Study 38714692 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 303
Study 38714786 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (10-80 mg, individually dosed)
Number of subjects: 185
Study 38714898 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dietary program (PDP)
Number of subjects: 347
Study 38714898 — intervention group
Group type: COMPARATOR
Intervention: General dietary advice (control)
Number of subjects: 347
Study 38714924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1% lidocaine
Number of subjects: 0
Study 38714924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38714926 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry directed feeding and 60 min/day of cycle ergometry
Number of subjects: 21
Study 38714926 — intervention group
Group type: COMPARATOR
Intervention: Standard weight-based empiric feeding and standard ICU physiotherapy
Number of subjects: 21
Study 38714926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry
Number of subjects: 21
Study 38714940 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 blood pressure measurements
Number of subjects: 5355
Study 38714940 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 hypertension status
Number of subjects: 5355
Study 38714940 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for increased BP
Number of subjects: 5355
Study 38714957 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intrinsic foot muscle exercise with a three-dimensional printing foot core training device
Number of subjects: 40
Study 38714999 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium yeast (200 µg/day) and coenzyme Q
Number of subjects: 414
Study 38714999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study 38715118 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-guided personalized mechanical ventilation
Number of subjects: 538
Study 38715118 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 538
Study 38715135 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk stabilization exercise (TSE)
Number of subjects: 60
Study 38715135 — intervention group
Group type: COMPARATOR
Intervention: Mulligan joint mobilization (MWM)
Number of subjects: 60
Study 38715135 — intervention group
Group type: COMPARATOR
Intervention: Isometric knee strengthening (KSE)
Number of subjects: 60
Study 38715140 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue-derived mesenchymal stem cell (AD-MSC) transplantation (2 infusions of 100 million cells i.v)
Number of subjects: 12
Study 38715179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 591
Study 38715179 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 591
Study 38715179 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 591
Study 38715621 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune tolerance induction (ITI) therapy with bortezomib, rituximab, methotrexate, and intravenous immunoglobulin over 6 months
Number of subjects: 8
Study 38715621 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune tolerance induction (ITI) therapy
Number of subjects: 8
Study 38716419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol (0.4 mg/kg for induction and 0.2 mg/kg for maintenance)
Number of subjects: 135
Study 38716419 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.0 mg/kg for induction and 1.0 mg/kg for maintenance)
Number of subjects: 135
Study 38716419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 135
Study 38716555 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 26
Study 38716555 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 26
Study 38716626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 970
Study 38716626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 970
Study 38716626 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 970
Study 38716987 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic distal gastrectomy (TLDG)
Number of subjects: 442
Study 38716987 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 442
Study 38717025 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome-based artificial intelligence-assisted personalized diet (PD)
Number of subjects: 121
Study 38717025 — intervention group
Group type: COMPARATOR
Intervention: Low-FODMAP diet (FODMAP)
Number of subjects: 121
Study 38717038 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly somatrogon (0.66 mg/kg/week)
Number of subjects: 0
Study 38717038 — intervention group
Group type: COMPARATOR
Intervention: Once-daily somatropin (0.24 mg/kg/week)
Number of subjects: 0
Study 38717075 — intervention group
Group type: EXPERIMENTAL
Intervention: D3S-001, a next-generation GDP-bound G12C inhibitor
Number of subjects: 0
Study 38717075 — intervention group
Group type: COMPARATOR
Intervention: Sotorasib and adagrasib (first-generation KRAS G12C inhibitors)
Number of subjects: 0
Study 38717237 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 516
Study 38717237 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 516
Study 38717424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate AMD eyes
Number of subjects: 502
Study 38717424 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AMD eyes
Number of subjects: 502
Study 38717424 — intervention group
Group type: COMPARATOR
Intervention: Healthy eyes
Number of subjects: 502
Study 38717424 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from early to intermediate AMD
Number of subjects: 502
Study 38717424 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall structural differences
Number of subjects: 502
Study 38717556 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 0
Study 38717556 — intervention group
Group type: COMPARATOR
Intervention: No beta blockers
Number of subjects: 0
Study 38717577 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 175
Study 38717596 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents living with obesity (ALwO)
Number of subjects: 649
Study 38717596 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of adolescents living with obesity (ALwO)
Number of subjects: 649
Study 38717596 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs)
Number of subjects: 649
Study 38717753 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiology-guided complete revascularization
Number of subjects: 1445
Study 38717753 — intervention group
Group type: COMPARATOR
Intervention: Culprit-only strategy
Number of subjects: 1445
Study 38717762 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Medical Home (TMH) intervention for 6 months delivered by a nurse care coordinator guided by an interdisciplinary team.
Number of subjects: 430
Study 38717762 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 430
Study 38717773 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid procedure (RP): 1 day of buprenorphine at minimum necessary dose, 1 opioid-free day, ascending low doses of oral naltrexone and adjunctive medications
Number of subjects: 415
Study 38717773 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (SP): approximately 5-day buprenorphine taper followed by a 7- to 10-day opioid-free period
Number of subjects: 415
Study 38717773 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid procedure (RP)
Number of subjects: 415
Study 38717773 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (SP)
Number of subjects: 415
Study 38717775 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic light labels
Number of subjects: 1065
Study 38717775 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity labels
Number of subjects: 1065
Study 38717775 — intervention group
Group type: COMPARATOR
Intervention: Beverage tax posters
Number of subjects: 1065
Study 38717775 — intervention group
Group type: COMPARATOR
Intervention: Snack machines
Number of subjects: 1065
Study 38717812 — intervention group
Group type: EXPERIMENTAL
Intervention: iJobs web-based intervention (2-week duration, 6 modules)
Number of subjects: 0
Study 38717812 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 38717861 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (DEC) 10-day schedule
Number of subjects: 606
Study 38717861 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy (IC) 3+7
Number of subjects: 606
Study 38717915 — intervention group
Group type: EXPERIMENTAL
Intervention: Overactive bladder (OAB) patients
Number of subjects: 221
Study 38717915 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 221
Study 38717915 — intervention group
Group type: EXPERIMENTAL
Intervention: OAB patients with higher OAB Questionnaire Short-Form scores
Number of subjects: 221
Study 38717931 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (12-month duration)
Number of subjects: 246
Study 38717993 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 0
Study 38717993 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative pembrolizumab
Number of subjects: 0
Study 38717993 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant atezolizumab
Number of subjects: 0
Study 38717993 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab with chemotherapy
Number of subjects: 0
Study 38717997 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (three sessions weekly for 8 weeks)
Number of subjects: 98
Study 38717997 — intervention group
Group type: COMPARATOR
Intervention: Physical activity counselling (control group)
Number of subjects: 98
Study 38718002 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT) delivered in the ED
Number of subjects: 336
Study 38718002 — intervention group
Group type: COMPARATOR
Intervention: No physiotherapy (no-PT group)
Number of subjects: 336
Study 38718135 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous polyclonal expanded regulatory T cells
Number of subjects: 0
Study 38718135 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38718169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 255
Study 38718169 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Proofing
Number of subjects: 255
Study 38718169 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Examen prayer practice
Number of subjects: 255
Study 38718169 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 255
Study 38718190 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 11
Study 38718190 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study 38718358 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy plus medical care
Number of subjects: 333
Study 38718358 — intervention group
Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 333
Study 38718430 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia (infraorbital nerve block)
Number of subjects: 100
Study 38718430 — intervention group
Group type: COMPARATOR
Intervention: No regional anesthesia
Number of subjects: 100
Study 38718430 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 100
Study 38718683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen intake in the evening/nighttime
Number of subjects: 1278
Study 38718683 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AI) intake
Number of subjects: 1278
Study 38718683 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ET intake timing
Number of subjects: 1278
Study 38718683 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis of ET intake timing and ET agent
Number of subjects: 1278
Study 38718786 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled breath analysis using secondary electrospray ionization high-resolution mass spectrometry
Number of subjects: 29
Study 38718923 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) and Artificial Intelligence (AI) model
Number of subjects: 9559
Study 38718924 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Iodine Intake (TII)
Number of subjects: 41
Study 38718924 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Iodine Excretion (TIE)
Number of subjects: 41
Study 38718924 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Iodine Excretion Rate (UIER)
Number of subjects: 41
Study 38718924 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Milk Iodine Excretion Rate (BMIER)
Number of subjects: 41
Study 38718924 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of iodine excreted in urine and breast milk
Number of subjects: 41
Study 38718924 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect of TII on BMIER when TII <120 μg/d
Number of subjects: 41
Study 38719277 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (carboplatin and paclitaxel in a 3 weekly scheme) followed by surgery
Number of subjects: 98
Study 38719277 — intervention group
Group type: COMPARATOR
Intervention: Primary chemoradiation (tumor dose of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for 6 weeks)
Number of subjects: 98
Study 38719280 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgenic anabolic steroids (AAS) use
Number of subjects: 180
Study 38719280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no previous AAS use)
Number of subjects: 180
Study 38719313 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD) 500 mg, two capsules two times per day for 7 days
Number of subjects: 74
Study 38719313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mannitol 312.5 mg), two matching capsules two times per day for 7 days
Number of subjects: 74
Study 38719320 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group (FET performed in the first menstrual cycle following the stimulated IVF cycle)
Number of subjects: 828
Study 38719320 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (FET performed at least in the second menstrual cycle following the stimulated IVF cycle)
Number of subjects: 828
Study 38719321 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDIAL-pivot group
Number of subjects: 99
Study 38719321 — intervention group
Group type: COMPARATOR
Intervention: CENTRAL-pivot group
Number of subjects: 99
Study 38719321 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported questionnaires
Number of subjects: 99
Study 38719321 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walking test
Number of subjects: 99
Study 38719321 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed up-and-go test
Number of subjects: 99
Study 38719321 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait analysis
Number of subjects: 99
Study 38719321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand test
Number of subjects: 99
Study 38719321 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-over test
Number of subjects: 99
Study 38719321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to step up and down stairs
Number of subjects: 99
Study 38719323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 1524
Study 38719323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1524
Study 38719328 — intervention group
Group type: EXPERIMENTAL
Intervention: EvolvRehab telerehabilitation for 6 weeks
Number of subjects: 0
Study 38719328 — intervention group
Group type: EXPERIMENTAL
Intervention: EvolvRehab telerehabilitation
Number of subjects: 0
Study 38719329 — intervention group
Group type: COMPARATOR
Intervention: Bacterial growth assessment in patients with MC1
Number of subjects: 0
Study 38719329 — intervention group
Group type: COMPARATOR
Intervention: Bacterial growth assessment in patients with MC2
Number of subjects: 0
Study 38719329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial growth assessment in previously operated patients
Number of subjects: 0
Study 38719329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial growth assessment in patients with large MCs
Number of subjects: 0
Study 38719329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial growth assessment from the vertebral body in the fusion group
Number of subjects: 0
Study 38719346 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative optical coherence tomography (OCT) morphological features
Number of subjects: 89
Study 38719346 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of subretinal hyper-reflective points (HRPs)
Number of subjects: 89
Study 38719346 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of foveal detachment
Number of subjects: 89
Study 38719346 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer retinal corrugations (ORCs)
Number of subjects: 89
Study 38719346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraretinal cystic spaces (ICS)
Number of subjects: 89
Study 38719346 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal involvement
Number of subjects: 89
Study 38719346 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal HRPs
Number of subjects: 89
Study 38719432 — intervention group
Group type: EXPERIMENTAL
Intervention: accelerated intermittent theta burst stimulation (iTBS) rTMS to the left dorsolateral prefrontal cortex (8 stimulation sessions of 600 pulses of iTBS/day for 3 days)
Number of subjects: 24
Study 38719432 — intervention group
Group type: EXPERIMENTAL
Intervention: accelerated intermittent theta burst stimulation (iTBS) rTMS
Number of subjects: 24
Study 38719500 — intervention group
Group type: EXPERIMENTAL
Intervention: SERCO model for predicting severe exacerbations
Number of subjects: 4065
Study 38719500 — intervention group
Group type: EXPERIMENTAL
Intervention: SERCO model for predicting COPD-specific readmissions
Number of subjects: 4065
Study 38719500 — intervention group
Group type: EXPERIMENTAL
Intervention: C-index for severe exacerbations
Number of subjects: 4065
Study 38719500 — intervention group
Group type: EXPERIMENTAL
Intervention: C-index for readmissions
Number of subjects: 4065
Study 38719500 — intervention group
Group type: COMPARATOR
Intervention: SERCO model vs prior severe exacerbation history
Number of subjects: 4065
Study 38719544 — intervention group
Group type: EXPERIMENTAL
Intervention: YSCH-01 (Recombinant L-IFN adenovirus)
Number of subjects: 14
Study 38719803 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (0.25-1 mg base/kg once daily given to the mother for 1-14 days)
Number of subjects: 0
Study 38719809 — intervention group
Group type: EXPERIMENTAL
Intervention: ATL-DC vaccination + poly-ICLC
Number of subjects: 0
Study 38719809 — intervention group
Group type: EXPERIMENTAL
Intervention: ATL-DC vaccination + resiquimod
Number of subjects: 0
Study 38719809 — intervention group
Group type: COMPARATOR
Intervention: ATL-DC vaccination
Number of subjects: 0
Study 38720025 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive and physical training
Number of subjects: 177
Study 38720113 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPE index for moderate pain
Number of subjects: 69
Study 38720113 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPE index for severe pain
Number of subjects: 69
Study 38720113 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPE index for pain-specific ED-II
Number of subjects: 69
Study 38720113 — intervention group
Group type: COMPARATOR
Intervention: NIPE index for emergence delirium
Number of subjects: 69
Study 38720113 — intervention group
Group type: COMPARATOR
Intervention: NIPE index for delirium-specific component ED-I
Number of subjects: 69
Study 38720251 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based cognitive training (warm-up module and three tasks including one-back and dual-N-back)
Number of subjects: 72
Study 38720251 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular VR headset app showing nature videos)
Number of subjects: 72
Study 38720312 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted index case testing (ICT)
Number of subjects: 26
Study 38720363 — intervention group
Group type: COMPARATOR
Intervention: SBIRT (Screening, Brief Intervention and Referral to Treatment) delivered by trained lay health workers, followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers.
Number of subjects: 750
Study 38720363 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care (control group).
Number of subjects: 750
Study 38720383 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rifampicin (35 mg/kg/day) plus levofloxacin added to standard TB treatment for the first 14 days
Number of subjects: 0
Study 38720383 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive corticosteroids (prednisone 1.5 mg/kg/day) for the first 14 days of TB treatment
Number of subjects: 0
Study 38720383 — intervention group
Group type: COMPARATOR
Intervention: Standard tuberculosis treatment
Number of subjects: 0
Study 38720383 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 0